Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. RSD1235 (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for RSD1235 (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. An additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, and an open-label safety study evaluating recent-onset AF patients, called ACT 4, are ( www.cardiome.com )
Cardiome Pharma Corp.
6190 Agronomy Rd. 6Th Floor
Vancouver, British Columbia V6T 1Z3
Canada
Tel: (604) 677-6905
Fax: (604) 677-6915